IMMIX BIOPHARMA INC (IMMX) Stock Price, Quote, News and Overview
NASDAQ:IMMX - Nasdaq - US45258H1068 - Common Stock - Currency: USD
IMMX Quote, Performance and Key Statistics
NASDAQ:IMMX (2/21/2025, 8:00:01 PM)
1.76
-0.02 (-1.12%)
The current stock price of IMMX is 1.76 USD. In the past month the price decreased by -14.15%. In the past year, price decreased by -42.11%.
IMMX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About IMMX
Company Profile
Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company is headquartered in Los Angeles, California and currently employs 14 full-time employees. The company went IPO on 2021-12-16. The firm is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and autoimmune disease. The firm's lead cell therapy asset is CAR-T NXC-201 for autoimmune disease, relapsed/refractory AL Amyloidosis, and relapsed/refractory multiple myeloma, which is being evaluated in its ongoing Phase Ib/IIa NEXICART-1 (NCT04720313) clinical trial. Its tissue specific therapeutic IMX-110 is in clinical trials as a monotherapy, and in combination with tislelizumab (BeiGene anti-PD-1 - IMMINENT-01 NCT05840835) for advanced solid tumors, such as relapsed/refractory colorectal cancer (CRC). IMX-110 in Phase Ib/IIa clinical trials, is a Tissue-Specific Therapeutic with TME Normalization, a technology that the Company is developing initially for mCRC and Soft Tissue Sarcoma (STS).
Company Info
IMMIX BIOPHARMA INC
11400 West Olympic Blvd., Suite 200
Los Angeles CALIFORNIA US
Employees: 16
Company Website: https://immixbio.com/
Investor Relations: https://www.immixbio.com/investor-relations/
Phone: 18889581084
IMMIX BIOPHARMA INC / IMMX FAQ
What is the stock price of IMMIX BIOPHARMA INC today?
The current stock price of IMMX is 1.76 USD. The price decreased by -1.12% in the last trading session.
What is the ticker symbol for IMMIX BIOPHARMA INC stock?
The exchange symbol of IMMIX BIOPHARMA INC is IMMX and it is listed on the Nasdaq exchange.
On which exchange is IMMX stock listed?
IMMX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for IMMIX BIOPHARMA INC stock?
7 analysts have analysed IMMX and the average price target is 7.14 USD. This implies a price increase of 305.68% is expected in the next year compared to the current price of 1.76. Check the IMMIX BIOPHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is IMMIX BIOPHARMA INC worth?
IMMIX BIOPHARMA INC (IMMX) has a market capitalization of 48.42M USD. This makes IMMX a Nano Cap stock.
How many employees does IMMIX BIOPHARMA INC have?
IMMIX BIOPHARMA INC (IMMX) currently has 16 employees.
What are the support and resistance levels for IMMIX BIOPHARMA INC (IMMX) stock?
IMMIX BIOPHARMA INC (IMMX) has a support level at 1.75 and a resistance level at 1.93. Check the full technical report for a detailed analysis of IMMX support and resistance levels.
Should I buy IMMIX BIOPHARMA INC (IMMX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of IMMX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of IMMX, evaluating the profitability, health, valuation and growth aspects
- IMMIX BIOPHARMA INC (IMMX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- IMMIX BIOPHARMA INC (IMMX) Sales and EPS estimates to see what analysts future expectations are.
- IMMIX BIOPHARMA INC (IMMX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- IMMIX BIOPHARMA INC (IMMX) Insider and Institutional Ownership to learn about the owners and their transactions.
- IMMIX BIOPHARMA INC (IMMX) Stock Chart to make your own analysis
- IMMIX BIOPHARMA INC (IMMX) Latest news and press-releases to stay up to date.
Does IMMIX BIOPHARMA INC (IMMX) stock pay dividends?
IMMX does not pay a dividend.
When does IMMIX BIOPHARMA INC (IMMX) report earnings?
IMMIX BIOPHARMA INC (IMMX) will report earnings on 2025-03-27, after the market close.
What is the Price/Earnings (PE) ratio of IMMIX BIOPHARMA INC (IMMX)?
IMMIX BIOPHARMA INC (IMMX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.88).
What is the Short Interest ratio of IMMIX BIOPHARMA INC (IMMX) stock?
The outstanding short interest for IMMIX BIOPHARMA INC (IMMX) is 2.04% of its float. Check the ownership tab for more information on the IMMX short interest.
IMMX Technical Analysis
IMMX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to IMMX. While IMMX seems to be doing ok healthwise, there are quite some concerns on its profitability.
IMMX Financial Highlights
Over the last trailing twelve months IMMX reported a non-GAAP Earnings per Share(EPS) of -0.88. The EPS increased by 7.22% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -87.07% | ||
| ROE | -124.73% | ||
| Debt/Equity | 0 |
IMMX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to IMMX. The Buy consensus is the average rating of analysts ratings from 7 analysts.